Area of research
Nephrology · Endocrinology, Diabetes and Metabolism · sun
Research interest
Research interests include Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management, Dialysis and Renal Disease Management, and Diabetes Management and Research.
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
Sex Differences in Long COVID
Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Performance of the American Heart Association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY
A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes
Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease
FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Combination therapy for kidney disease in people with diabetes mellitus
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Frailty, Multimorbidity, and Polypharmacy
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
Reframing Chronicity with Urgency in Chronic Kidney Disease Management
Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study
Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis
Development and Validation of the American Heart Association’s PREVENT Equations
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial